October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.
It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.
This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.
“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.
“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”
In 2022, JKTG Foundation work focuses on rethinking health care quality, emerging cancer research, and uses for real-world evidence. Of particular interest is building collaboration by fostering multi-institutional and multi-disciplinary research in the area of breast cancer metastasis.
I am a professional race car driver. We race at speeds of 170-180 mph, at night, in the rain, and with lots of other cars on the track. There are television commentators and announcers at the track who render commentary but many have never driven race cars at our level so can’t truly understand what we’re doing.
It’s become a bit of a tradition for the Foundation to send a Thanksgiving note, and this year we’re excited to support projects that have evolved as part of ongoing work by researchers and the Foundation.